Scientists skeptical over Chinese firm’s Covid-19 drug claims, firm’s stocks surge
Chinese biotech firm Kintor Pharmaceutical Limited saw its stock price jump by more than 20% the day after it announced on April 25 that it had “completed the first patient enrollment and dosing” in a late-stage U.S. clinical trial of its experimental COVID-19 treatment. It was the company’s latest announcement about the progress of the…